Genmab price target raised to $70 from $50 at H.C. Wainwright
The substantial target increase supports a cautiously bullish view, though it reflects one analyst's estimate.
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The substantial target increase supports a cautiously bullish view, though it reflects one analyst's estimate.
What happened, with direct paths to the underlying reporting
H.C. Wainwright raised its GMAB target 40% to $70, about 22% above the posted price of $57.29. This is a bullish analyst opinion, not a company announcement.
Target: $70
Posted price: $57.29
Analyst firm: H.C. Wainwright
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.